Go to content
UR Home

Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na+?

URN to cite this document:
urn:nbn:de:bvb:355-epub-513686
DOI to cite this document:
10.5283/epub.51368
Trum, Maximilian ; Riechel, Johannes ; Wagner, Stefan
[img]
Preview
License: Creative Commons Attribution 4.0
PDF - Published Version
(2MB)
Date of publication of this fulltext: 11 Jan 2022 14:42


Abstract

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are emerging as a new treatment strategy for heart failure with reduced ejection fraction (HFrEF) and—depending on the wistfully awaited results of two clinical trials (DELIVER and EMPEROR-Preserved)—may be the first drug class to improve cardiovascular outcomes in patients suffering from heart failure with preserved ejection fraction (HFpEF). ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de
0941 943 4239

Dissertations: dissertationen@ur.de
0941 943 3904

Research data: daten@ur.de
0941 943 4239

Contact persons